Hot Clean Energy Stocks To Invest In 2018

Related CLNE 20 Biggest Mid-Day Losers For Friday Mid-Day Market Update: ConforMIS Gains Following Strong Q3 Results; MDC Partners Shares Drop Clean Energy Fuels Corp. – Bridge Funding For A Bridge Fuel (Seeking Alpha)
Related FRO Earnings Scheduled For November 29, 2016 Mid-Morning Market Update: Markets Mixed; Campbell Soup Profit Misses Estimates Frontline's (FRO) CEO Robert McLeod on Q3 2016 Results – Earnings Call Transcript (Seeking Alpha)

 

Toward the end of trading Wednesday, the Dow traded down 0.35 percent to 18,388.83 while the NASDAQ declined 0.25 percent to 5,209.89. The S&P also fell, dropping 0.36 percent to 2,168.24.

Leading and Lagging Sectors

Wednesday afternoon, non-cyclical consumer goods & services shares gained by 0.10 percent..

In trading on Wednesday, energy shares fell by 1.72 percent. Meanwhile, top losers in the sector included Clean Energy Fuels Corp (NASDAQ: CLNE), down 5 percent, and Frontline Ltd. (NYSE: FRO), down 7 percent.

Hot Clean Energy Stocks To Invest In 2018: Watts Water Technologies, Inc.(WTS)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Watts Water Technologies (NYSE: WTS) and ARC Group WorldWide (NASDAQ:ARCW) are both computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

  • [By Stephan Byrd]

    A number of institutional investors and hedge funds have recently made changes to their positions in WTS. SeaCrest Wealth Management LLC acquired a new position in Watts Water Technologies during the fourth quarter worth about $112,000. Xact Kapitalforvaltning AB acquired a new position in shares of Watts Water Technologies in the fourth quarter valued at approximately $224,000. Sawgrass Asset Management LLC acquired a new position in shares of Watts Water Technologies in the fourth quarter valued at approximately $270,000. Koch Industries Inc. raised its position in shares of Watts Water Technologies by 22.0% in the fourth quarter. Koch Industries Inc. now owns 3,821 shares of the technology company’s stock valued at $290,000 after buying an additional 690 shares during the last quarter. Finally, Quadrature Capital Ltd acquired a new position in shares of Watts Water Technologies in the fourth quarter valued at approximately $330,000. Institutional investors own 77.22% of the company’s stock.

    ILLEGAL ACTIVITY NOTICE: “Watts Water Technologies (WTS) Expected to Post Quarterly Sales of $362.52 Million” was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at www.tickerreport.com/banking-finance/3380368/watts-water-technologies-wts-expected-to-post-quarterly-sales-of-362-52-million.html.

    Watts Water Technologies Company Profile

Hot Clean Energy Stocks To Invest In 2018: Sage Therapeutics, Inc.(SAGE)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    The Good

    The market remains resistant (Rs over Ss and Ns). Brokerages, banks and insurance companies continue their league-leading strength. The Russell 2000 Index is up for the 15th consecutive day. Retail extends yesterday’s strength. Nordstrom (JWN) , Macy’s (M) , Best Buy (BBY) , Target (TGT) , Walmart (WMT) , Foot Locker (FL) and JCPenney (JCP) are strong. First day down for Amazon (AMZN) . Agricultural commodities are lackluster, but soybeans are up another up $0.05 today, up substantially for three days in a row. Speculative biotech (Sage (SAGE) , FibroGen (FGEN) , Acadia Pharmaceuticals (ACAD) and Aerie Pharmaceuticals  (AERI) ) stronger after recent weakness. Ag equipment up big time after the Deere (DE) beat.

    The Bad

  • [By Chris Lange]

    Shares of Sage Therapeutics Inc. (NASDAQ: SAGE) saw an incredible gain on Thursday after the firm announced positive top-line results from its midstage trial. Specifically, the firm reported results from its Phase 2 trial of Sage-217 for the treatment of moderate to severe major depressive disorder (MDD).

  • [By ]

    Cramer was bearish on Geron (GERN) , Mitek Systems (MITK) , AK Steel Holding (AKS) , Sage Therapeutics (SAGE) and AbbVie (ABBV) .

    Search Jim Cramer’s “Mad Money” trading recommendations using our exclusive “Mad Money” Stock Screener.

  • [By WWW.THESTREET.COM]

    Position: Long GLD small, bonds, SDS; short TLT small, SPY small .

Hot Clean Energy Stocks To Invest In 2018: SK TELECOM ADR EACH REP 1/9 KRW500(CIT)

Advisors’ Opinion:

  • [By Lisa Abramowicz]

    There was this maturity wall that people were terrified of, said Neil Wessan, the group head of New York-based CIT Group Inc. (CIT)s capital markets unit. Thats been spread out over a much broader period of time.

  • [By Ben Levisohn]

    We will admit that these latter assumptions are somewhat arbitrary, but nevertheless we cannot help escape the view that in 2017 everything will likely be at least a little adverse to prior expectations. On average our estimate reductions are 8%, and range from 3% at CIT Group (CIT) to 13% at Goldman Sachs. With that, we are lowering our PT of Bank of America,Citigroup andGoldman Sachs from $20, $70 and $243 to $18, $63 and $214, respectively…

Hot Clean Energy Stocks To Invest In 2018: Cellectis S.A.(CLLS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Cellectis SA (ADR) (NASDAQ: CLLS) shares dropped 20 percent to $25.70 after announcing FDA clinical hold of UCART123 studies.

    Shares of Opiant Pharmaceuticals Inc (NASDAQ: OPNT) were down 10 percent to $35.20. Opiant Pharma named David O'Toole as CFO.

  • [By Jim Robertson]

    Yesterday, small cap clinical-stage biopharmaceutical stock Cellectis SA (NASDAQ: CLLS) reported that they had received notice fromFDA that a clinical hold was placed on both UCART123 ongoing Phase 1 studies -in acute myeloid leukemia (AML) and in blastic plasmacytoid dendritic cell neoplasm (BPDCN). The clinical hold was initiated after Cellectis reported one fatality in the BPDCN clinical trial (ABC study) with the Company now working closelywith the investigators and the FDA in order to resume the trials with an amended protocol including a lowered dosing of UCART123. The FDA has a detailed page about clinical holds which mentions:

Hot Clean Energy Stocks To Invest In 2018: PHI, Inc.(PHIIK)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Thursday, our Under the Radar Moversnewsletter suggested shorting small cap offshore oil and gas services stock PHI Inc (NASDAQ: PHIIK):

    We’re a little bit late to the party here, but that’s ok – there’s still some meat left on the bone, so to speak. Were looking for the stock to continue on to the lower edge of a long-term (and bearish) trading range that should allow it to peel back to at least the lower $12’s. We’ve see PHIIK shares tumble with great speed and distance a couple of times already, and we’re about halfway through round three.

Leave a Reply

Your email address will not be published. Required fields are marked *